Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$720,000 |
 |
Gilead SciencesGILD |
-$3.5B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$6.1M |
 |
Crispr TherapeuticsCRSP |
-$164M |
Are Pliant Therapeutics Insiders Buying or Selling?
Pliant Therapeutics (PLRX) has had no reported insider transactions in the past 90 days. The most recent was Cummings Keith Lamont, who sold 24,002 shares at $1.28 on January 20, 2026.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the PLRX AI Score. For government officials trading this stock, see PLRX congressional trading.
Who’s Trading Pliant Therapeutics Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| Bernard Coulie | Sold $700,000 | 2 | Jan 20, 2026 |
| Mike Ouimette | Sold $260,000 | 2 | Jan 22, 2025 |
| Cummings Keith Lamont | Sold $260,000 | 2 | Jan 20, 2026 |
| Eric Lefebvre | Sold $210,000 | 1 | Jan 17, 2025 |
| Hans Hull | Sold $180,000 | 1 | Jan 17, 2025 |
| Lily Cheung | Sold $52,000 | 2 | Jan 20, 2026 |
Recent Pliant Therapeutics Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Cummings Keith Lamont | Jan 20, 2026 | Sell | 24,002 | $1.28 | $31,000 |
| Bernard Coulie | Jan 20, 2026 | Sell | 89,375 | $1.28 | $110,000 |
| Lily Cheung | Jan 20, 2026 | Sell | 7,534 | $1.28 | $9,600 |
| Minnie Kuo | Jan 20, 2026 | Sell | 6,917 | $1.28 | $8,900 |
| Mike Ouimette | Jan 22, 2025 | Sell | 10,230 | $10.99 | $110,000 |
| Bernard Coulie | Jan 17, 2025 | Sell | 52,419 | $11.2 | $590,000 |
| Cummings Keith Lamont | Jan 17, 2025 | Sell | 20,148 | $11.2 | $230,000 |
| Hans Hull | Jan 17, 2025 | Sell | 15,936 | $11.2 | $180,000 |
| Eric Lefebvre | Jan 17, 2025 | Sell | 18,478 | $11.2 | $210,000 |
| Mike Ouimette | Jan 17, 2025 | Sell | 13,270 | $11.2 | $150,000 |
| Lily Cheung | Jan 17, 2025 | Sell | 3,740 | $11.2 | $42,000 |
Frequently Asked Questions: Pliant Therapeutics Insider Trading
Pliant Therapeutics insiders have not reported any transactions in the past 90 days.
The most recent sale was by Cummings Keith Lamont who sold 24,002 shares on January 20, 2026. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Coulie Bernard has sold the most PLRX stock in the last 2 years, with a total value of $700,000.
The total value of insider transactions for Pliant Therapeutics in the last 2 years is negative, amounting to -$1.7M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
